Media Coverage header image
 |
|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Dialysis company Neway said Thursday that it has entered a strategic lab services arrangement with Quest Diagnostics to speed dialysis lab testing and reduce testing costs for patients with end-stage renal disease (ESRD). Under the terms of the agreement, Neway will use Quest's lab network to provide local testing services, enabling next-day results while also reducing sample transportation costs.
Self-service has seen incredible growth in recent years, and this is just the beginning. 81% of customers want more self-service options. Here are 20 of the best examples of self-service:
13. Quest Diagnostics Cuts Wait Time with Kiosks
Medical lab company Quest Diagnostics cuts wait times with interactive kiosks that patients can use to check in, upload insurance information, and make payments. The devices help patients be seen faster, allowing medical staff to spend more time working with patients and less on administrative tasks.
Stamford-based Americares is partnering with Quest Diagnostics to provide 10 clinics across the U.S. with no-cost diagnostic services for one year as a means of increasing access to care for low-income, uninsured and underinsured patients.
Rutgers and Quest Diagnostics are expanding their collaboration to further improve access to critical primary care services for uninsured patients of the university’s Health Outreach Practice Experience (H.O.P.E.) Clinic in Plainfield. Resources from the Quest Diagnostics Foundation will enable the clinic to double its capacity by providing primary care services for a second day of the week.
Quest Diagnostics has secured breakthrough device designation for its adeno-associated virus (AAV) test, AAVrh74 ELISA assay, from the US Food and Drug Administration (FDA). The test is an enzyme-linked immunosorbent in vitro diagnostic assay intended for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in the serum of humans. Quest also expanded collaboration with Sarepta to develop complementary diagnostics for Sarepta's gene therapies.